Necroptosis in Intestinal Inflammation and Cancer: New Concepts and Therapeutic Perspectives

• Main Authors: Anna Negroni, Eleonora Colantoni, Salvatore Cucchiara, Laura Stronati
• Format: Article
• Language: English
• Published: MDPI AG 2020-10-01
• Series: Biomolecules
• Subjects: programmed cell death; inflammation; cancer; intestinal diseases; inhibitors
• Online Access: https://www.mdpi.com/2218-273X/10/10/1431

Necroptosis is a caspases-independent programmed cell death displaying intermediate features between necrosis and apoptosis. Albeit some physiological roles during embryonic development such tissue homeostasis and innate immune response are documented, necroptosis is mainly considered a pro-inflammatory cell death. Key actors of necroptosis are the receptor-interacting-protein-kinases, RIPK1 and RIPK3, and their target, the mixed-lineage-kinase-domain-like protein, MLKL. The intestinal epithelium has one of the highest rates of cellular turnover in a process that is tightly regulated. Altered necroptosis at the intestinal epithelium leads to uncontrolled microbial translocation and deleterious inflammation. Indeed, necroptosis plays a role in many disease conditions and inhibiting necroptosis is currently considered a promising therapeutic strategy. In this review, we focus on the molecular mechanisms of necroptosis as well as its involvement in human diseases. We also discuss the present developing therapies that target necroptosis machinery.